Alex DePaoli, M.D.

Vice President, Clinical Research

Dr. DePaoli has more than 16 years of experience in the diabetes, obesity and metabolic disease fields. He trained in Clinical and Molecular Endocrinology at the University of Chicago with Dr. Kenneth Polonski and in the Howard Hughes laboratory of Dr. Graham Bell. His clinical and research interests in diabetes and obesity were focused during his work at the Sansum Diabetes Research Institute with Dr. Lois Jovanovich, which led him to join Amgen in 1998 to develop their metabolic disease group. His work at Amgen was pivotal in enabling multiple clinical applications of the adipocytokine Leptin. Dr. DePaoli has worked on a broad array of cardio-metabolic, muscle and bone disease targets with a focus on translating novel pathways into the clinic. These pathways include: 11 Beta HSD-1, Myostatin, RANK Ligand, IL-1 receptor, Calcium Sensing Receptor, PPAR-gamma modulation, DPP-4, and MCH-R1. Dr. DePaoli joined InteKrin Therapeutics in 2007 as Chief Medical Officer to continue the clinical development of a Selective PPAR-gamma Modulator. He also maintains a clinical endocrinology practice at the Sansum Diabetes Research Institute.